Table 2.

BRAF mutation in cholangiocarcinoma of the liver

Patient No	Stage	Grade	Nucleotide	Amino acid substitution
5	I	1	1796  T→A	599  Valine→glutamate
9	II	2	1403  G→T	468  Glycine→alanine
22	II	1	1796  T→A	599  Valine→glutamate
23	IIIA	3	1796  T→A	599  Valine→glutamate
30	II	2	1796  T→A	599  Valine→glutamate
32	IIIA	2	1786  C→G	596  Leucine→valine
33	IIIC	2	1796  T→A	599  Valine→glutamate
36	IIIC	2	1796  T→A	599  Valine→glutamate
37	II	2	1782  T→G	594  Phenylalanine→leucine
40	II	1	1796  T→A	599  Valine→glutamate
51	I	1	1403  G→A	468  Glycine→glutamate
53	IIIA	3	1796  T→A	599  Valine→glutamate
58	II	2	1796–97  TG→AT	599  Valine→aspartate
61	II	2	1796–97  TG→AT	599  Valine→aspartate
63	II	2	1796  T→A	599  Valine→glutamate
54	Non-neoplastic liver		1388  G→A	463  Glycine→glutamate